secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001558370-21-015398
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx Q3 net loss $25.9M ($0.59/sh); cash $143.6M; R&D spend jumps
---------------------------------------------------------------------

- Net loss $25.9M ($0.59 loss per share) vs $6.4M ($0.17) YoY; license revenue $6.9M.
- R&D expenses surged to $21.6M from $4.6M on clinical trial and manufacturing costs.
- Cash and equivalents $143.6M; expects funding into Q2 2023.
- Phase 3 Lumeos trial for XLRP screening; AQUAx xerostomia Phase 1 enrollment to complete Q4 2021.
- IND planned for AAV-GAD in Parkinson's and Phase 3 pivotal trial for AAV-RPE65 in early 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837021015398/0001558370-21-015398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837021015398/mgtx-20211110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-015398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer